Odontogenic tumors (TOs) consist of a group of heterogeneous lesions of varied clinical and histological behavior, derived from the epithelium, ectomesenchyma and/ or mesenchyma of the dental apparatus or its remnants. They range from tumor malformations (hamartomas) to benign neoplasms and metastatic malignancies. They are rare entities composing only 1% of the tumors of the maxillofacial region, making specific protocols and therapeutic guidelines not available. Early diagnosis and good therapeutic planning contribute to a better prognosis. Objectives: The objective of this study was to perform a retrospective clinical and pathological analysis of the TOs, in order to establish casuistry in our service. Methods: We performed a retrospective survey of the patients who developed TOs from 1980 and were treated in our institution. Clinicopathological data were collected from medical records with the aid of a standardized record for the study. Histopathological analysis of H&E slides was performed for histological confirmation of tumor types. Results: In this study, 73 patients who had OTs were analyzed. The age ranged from 2 to 78 years, with an average of 36.4 years. A total of 48 (65.75%) were female patients, and 25 (34.25%) were male patients. A total of 46 patients (63%) presented with involvement of the mandible. The maxilla was affected in 21 of the cases (28.76%). As for the histopathological report, 13 (17,80%) were ameloblastoma, 10 (13.69%) odontogenic tumor, eight (10.59%) odontogenic cyst without any other specification, four (5.47%) dendritic cysts, fibromas, two (2.74%) composite odontomas, one (1.37%) complex odontoma, and one mixed odontoma, one myxoma, one fibrous dysplasia with associated aneurysmal cyst, one cyst odontogenic calcifying, one fibro-odontoma, and 25 unspecified cases.
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Conclusion:
The collected samples added epidemiological data to the literature and covered the main histological subtypes of TOs, including some rare ones. The data contribute to international indexes and reinforce clinicopathological findings of these tumors. Introduction: Partial thromboplastin time (PTT) is one of the most commonly used laboratory tests for evaluation of hemostasis. However, prolonged PTT can be paradoxical clinically, either due to bleeding disorder (factor deficiency) or thrombophilic situation (anticoagulation agents/inhibitors). It is crucial to understand the common etiologies for prolonged PTT in the interpretation of abnormal PTT results and the related patient management.
Methods and Materials:
This study reviews the commonly used anticoagulation medications in patients with prolonged PTT and the possible etiologies for prolonged PTT in these patients. A total of 1,140 patients were identified with prolonged PTT at the coagulation laboratory at William Beaumont Hospital in Troy, Michigan, from August 2015 to April 2016. Electronic medical charts of these patients were reviewed for anticoagulation/antithrombotic medications, including warfarin, direct oral anticoagulants (apixaban, rivaroxaban and dabigatran, or direct oral anticoagulants [DOACs]), heparin, low molecular weight heparin (LMWH) and anti-platelet agents (aspirin, Plavix, prasugrel, and ticagrelor). Results: Among the 1,140 patients, 873 (76.6%) were receiving one or more anticoagulation medications at the time with prolonged PTT, and 267 (23.4%) patients had no anticoagulation medications. In patients receiving anticoagulation medications, the numbers of medications were as follows: 281 warfarin (32.2%), 232 DOACs (26.6%), 27 heparin/LMWH (3.1%), and 333 anti-platelet agents (38.1%). There were 390 (44.7%) patients receiving two or more anticoagulation medications, and the most common second anticoagulation medication was aspirin, seen in 376 patients (43.1%). Conclusion: In this study, the majority (76.6%) of patients with prolonged PTT were receiving one or more anticoagulation/antithrombotic medications. Nearly half (47.4%) of them received warfarin, heparin/LMWH, and/or DOACs, which are likely the causes of prolonged PTT. Anti-platelet agents were seen in another 29.2% of patients, indicative of thrombophilic condition in these patients. The remaining (23.4%) patients received no anticoagulation/antithrombotic medications, and the prolonged PTT may be an indication for the evaluation of possible underlying bleeding disorders. Introduction: Measurement of coagulation assay is pivotal all across in different specialties in field of medicine. We compared prothrombin time, activated prothrombin time and fibrinogen from fresh blood samples drawn into glass vs. plastic tubes. There was a recent recall of glass tubes nationwide from a leading manufacture. This type
